ResMed Inc. (RMD)
| Market Cap | 28.70B -23.0% |
| Revenue (ttm) | 5.54B +10.3% |
| Net Income | 1.52B +15.7% |
| EPS | 10.37 +16.4% |
| Shares Out | 144.24M |
| PE Ratio | 19.19 |
| Forward PE | 16.89 |
| Dividend | $2.40 (1.21%) |
| Ex-Dividend Date | May 14, 2026 |
| Volume | 1,284,197 |
| Open | 201.19 |
| Previous Close | 202.76 |
| Day's Range | 198.22 - 203.04 |
| 52-Week Range | 180.27 - 293.81 |
| Beta | 0.78 |
| Analysts | Buy |
| Price Target | 252.20 (+26.74%) |
| Earnings Date | Aug 6, 2026 |
About RMD
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally. The company operates in two segments, Sleep and Breathing Health, and Residential Care Software. It offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring... [Read more]
Financial Performance
In fiscal year 2025, ResMed's revenue was $5.15 billion, an increase of 9.84% compared to the previous year's $4.69 billion. Earnings were $1.40 billion, an increase of 37.20%.
Financial StatementsAnalyst Summary
According to 18 analysts, the average rating for RMD stock is "Buy." The 12-month stock price target is $252.2, which is an increase of 26.74% from the latest price.
News
ResMed downgraded to Sector Perform from Outperform at RBC Capital
RBC Capital downgraded ResMed (RMD) to Sector Perform from Outperform with a price target of $234, down from $276. ResMed faces a number of challenges in FY27, including device sales…
ResMed price target lowered to $220 from $235 at Mizuho
Mizuho lowered the firm’s price target on ResMed (RMD) to $220 from $235 and keeps an Outperform rating on the shares. The firm adjusted targets in the medical device and…
ResMed downgraded to Neutral from Buy at Citi
Citi analyst Laura Sutcliffe downgraded ResMed (RMD) to Neutral from Buy with a price target of $235, down from $270. The firm sees the company’s earnings growth dropping in fiscal…
ResMed price target lowered to $225 from $240 at Jefferies
Jefferies lowered the firm’s price target on ResMed (RMD) to $225 from $240 and keeps a Hold rating on the shares. Recent developments at ResMed, including the MatrixCare divestiture, Noctrix…
ResMed price target lowered to $276 from $321 at RBC Capital
RBC Capital lowered the firm’s price target on ResMed (RMD) to $276 from $321 and keeps an Outperform rating on the shares to reflect the company having announced the sale…
ResMed price target lowered to $225 from $227 at Wells Fargo
Wells Fargo lowered the firm’s price target on ResMed (RMD) to $225 from $227 and keeps an Equal Weight rating on the shares. The company announced the sale of MatrixCare,…
ResMed to sell software business MatrixCare for $490 million
ResMed said on Tuesday it would sell its software business MatrixCare to private equity firm Frazier Healthcare Partners for $490 million in cash, as the health technology company sharpens its focus...
Frazier to acquire MatrixCare from ResMed, terms not disclosed
Frazier Healthcare Partners, a private equity firm focused exclusively on the healthcare industry, announced it has entered into a definitive agreement to acquire MatrixCare from ResMed (RMD). “Frazie...
Frazier Healthcare Partners Announces Definitive Agreement to Acquire MatrixCare
SEATTLE--(BUSINESS WIRE)--Frazier Healthcare Partners ("Frazier"), a private equity firm focused exclusively on the healthcare industry, today announced it has entered into a definitive agreement to a...
ResMed to sell MatrixCare business to Frazier Healthcare, terms undisclosed
Resmed (RMD) announced it has entered into a definitive agreement to sell its MatrixCare business to Frazier Healthcare Partners. The transaction includes MatrixCare and related software offerings his...
Resmed Announces Agreement to Sell MatrixCare Business
SAN DIEGO, July 07, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced it has ente...
ResMed Slides: Divestiture of MatrixCare presentation
ResMed has posted slides in relation to its latest quarterly earnings report, which was published on July 7, 2026.
ResMed added to APAC Conviction List at Goldman Sachs
Goldman Sachs analysts added ResMed (RMD) to the firm’s APAC Conviction List as part of its monthly update. The firm expects continuous airway pressure therapy patient growth for the company.
Resmed to Report Fourth Quarter Fiscal 2026 Earnings on August 6, 2026
SAN DIEGO, June 30, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the fourth quarter of fiscal year 2026 on Thursday, ...
ResMed price target lowered to $266 from $290 at KeyBanc
KeyBanc lowered the firm’s price target on ResMed (RMD) to $266 from $290 and keeps an Overweight rating on the shares. Last week’s attendance at the SLEEP APSS Meeting in…
ResMed downgraded to Equal Weight from Overweight at Morgan Stanley
Morgan Stanley analyst David Bailey downgraded ResMed (RMD) to Equal Weight from Overweight with a price target of $230, down from $286. The company has posted annual earnings growth of…
ResMed price target lowered to $270 from $340 at Citi
Citi lowered the firm’s price target on ResMed (RMD) to $270 from $340 and keeps a Buy rating on the shares. The says the company’s fundamentals are intact despite the…
Angelini Ventures Marks First Portfolio Company Exit as ResMed Acquires Noctrix Health for $340 million
Angelini Ventures marks its first portfolio exit as ResMed acquires Noctrix Health, validating its strategy of backing breakthrough healthcare innovation.
ResMed Transcript: 46th Annual William Blair Growth Stock Conference
Operating in a vast, under-penetrated market, the company leverages innovation, strategic acquisitions, and digital health partnerships to drive growth and patient engagement. Strong financial performance supports increased R&D, share buybacks, and expansion into new therapy areas like Restless Legs Syndrome.
ResMed Slides: 46th Annual William Blair Growth Stock Conference
ResMed has posted slides in relation to its latest quarterly earnings report, which was published on June 2, 2026.
Resmed Completes Acquisition of Noctrix Health, Expanding Clinical Sleep Health Portfolio
Acquisition adds Nidra® Tonic Motor Activation (TOMAC) Therapy, an FDA De Novo classified, nonpharmacologic treatment designed to address moderate-to-severe Restless Legs Syndrome (RLS). Acquisition a...
Resmed Announces Participation in the 46th Annual William Blair Growth Stock Conference
SAN DIEGO, May 19, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chairman and chief executive officer, and Aaron Bloomer, chief financial officer, will attend the...
ResMed, Oura partner to expand access to sleep health education
Resmed (RMD) and Oura announced they are partnering to expand access to sleep health education and pathways to care. By connecting consumer-generated wellness insights with Resmed’s sleep health resou...
Resmed and ŌURA Partner to Expand Access to Sleep Health Education and Care
SAN DIEGO, May 19, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, and ŌURA, maker of the world...
ResMed price target lowered to $225 from $254 at Baird
Baird lowered the firm’s price target on ResMed (RMD) to $225 from $254 and keeps a Neutral rating on the shares. The firm updated its model following Q3 results and…